Addex Therapeutics Ltd (ADXN.SW)
CHF 0.05
(0.0%)
CHF 0.05
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.52 Million CHF | 46.52% |
| 2022 | -6.58 Million CHF | 67.08% |
| 2021 | -20 Million CHF | -10.34% |
| 2020 | -18.12 Million CHF | 41.5% |
| 2019 | -30.98 Million CHF | 25.64% |
| 2018 | -41.67 Million CHF | -1508.55% |
| 2017 | -2.59 Million CHF | -82.9% |
| 2016 | -1.41 Million CHF | 46.22% |
| 2015 | -2.63 Million CHF | -33.04% |
| 2014 | -1.97 Million CHF | 32.05% |
| 2013 | -2.91 Million CHF | 80.9% |
| 2012 | -15.25 Million CHF | 57.7% |
| 2011 | -36.06 Million CHF | 43.47% |
| 2010 | -63.79 Million CHF | 16.67% |
| 2009 | -76.56 Million CHF | 35.92% |
| 2008 | -119.47 Million CHF | 14.69% |
| 2007 | -140.04 Million CHF | -243.08% |
| 2006 | -40.82 Million CHF | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -3.75 Million CHF | -135.81% |
| 2024 Q1 | -1.59 Million CHF | 54.77% |
| 2023 Q3 | -4.43 Million CHF | 36.12% |
| 2023 Q4 | -3.52 Million CHF | 20.53% |
| 2023 FY | -3.52 Million CHF | 46.52% |
| 2023 Q2 | -6.93 Million CHF | -30.0% |
| 2023 Q1 | -5.33 Million CHF | 18.96% |
| 2022 FY | -6.58 Million CHF | 67.08% |
| 2022 Q4 | -6.58 Million CHF | 34.0% |
| 2022 Q3 | -9.97 Million CHF | -17.7% |
| 2022 Q1 | -14.47 Million CHF | 27.64% |
| 2022 Q2 | -8.47 Million CHF | 41.44% |
| 2021 Q2 | -17.68 Million CHF | 28.48% |
| 2021 FY | -20 Million CHF | -10.34% |
| 2021 Q1 | -24.73 Million CHF | -36.42% |
| 2021 Q4 | -20 Million CHF | -33.67% |
| 2021 Q3 | -14.96 Million CHF | 15.4% |
| 2020 FY | -18.12 Million CHF | 41.5% |
| 2020 Q1 | -26.66 Million CHF | 13.94% |
| 2020 Q3 | -17.54 Million CHF | 13.6% |
| 2020 Q4 | -18.12 Million CHF | -3.32% |
| 2020 Q2 | -20.3 Million CHF | 23.85% |
| 2019 Q1 | 41.67 Million CHF | 200.0% |
| 2019 Q2 | -36.35 Million CHF | -187.24% |
| 2019 Q4 | -30.98 Million CHF | 0.0% |
| 2019 FY | -30.98 Million CHF | 25.64% |
| 2018 Q2 | -43.57 Million CHF | 0.0% |
| 2018 Q1 | -43.57 Million CHF | -1582.02% |
| 2018 Q3 | -41.67 Million CHF | 4.37% |
| 2018 FY | -41.67 Million CHF | -1508.55% |
| 2018 Q4 | -41.67 Million CHF | 0.0% |
| 2017 FY | -2.59 Million CHF | -82.9% |
| 2017 Q4 | -2.59 Million CHF | -0.44% |
| 2017 Q3 | -2.57 Million CHF | 27.84% |
| 2017 Q2 | -3.57 Million CHF | 0.0% |
| 2017 Q1 | -3.57 Million CHF | -152.37% |
| 2016 Q2 | -2.25 Million CHF | 0.0% |
| 2016 Q4 | -1.41 Million CHF | 0.0% |
| 2016 Q3 | -1.41 Million CHF | 37.18% |
| 2016 Q1 | -2.25 Million CHF | 14.39% |
| 2016 FY | -1.41 Million CHF | 46.22% |
| 2015 Q4 | -2.63 Million CHF | 0.0% |
| 2015 FY | -2.63 Million CHF | -33.04% |
| 2015 Q2 | -3.57 Million CHF | 0.0% |
| 2015 Q1 | -3.57 Million CHF | -80.81% |
| 2015 Q3 | -2.63 Million CHF | 26.42% |
| 2014 Q2 | -2.09 Million CHF | 0.0% |
| 2014 Q4 | -1.97 Million CHF | 0.0% |
| 2014 Q3 | -1.97 Million CHF | 5.45% |
| 2014 FY | -1.97 Million CHF | 32.05% |
| 2014 Q1 | -2.09 Million CHF | 28.13% |
| 2013 Q2 | -4.47 Million CHF | 0.0% |
| 2013 Q1 | -4.47 Million CHF | 70.64% |
| 2013 FY | -2.91 Million CHF | 80.9% |
| 2013 Q4 | -2.91 Million CHF | 0.0% |
| 2013 Q3 | -2.91 Million CHF | 34.95% |
| 2012 Q4 | -15.25 Million CHF | 0.0% |
| 2012 Q3 | -15.25 Million CHF | 24.61% |
| 2012 FY | -15.25 Million CHF | 57.7% |
| 2012 Q2 | -20.23 Million CHF | 0.0% |
| 2011 Q4 | -36.06 Million CHF | 0.0% |
| 2011 FY | -36.06 Million CHF | 43.47% |
| 2011 Q2 | -50.23 Million CHF | 0.0% |
| 2010 Q2 | -56.68 Million CHF | 0.0% |
| 2010 Q4 | -63.79 Million CHF | 0.0% |
| 2010 FY | -63.79 Million CHF | 16.67% |
| 2009 FY | -76.56 Million CHF | 35.92% |
| 2009 Q4 | -76.56 Million CHF | 0.0% |
| 2008 FY | -119.47 Million CHF | 14.69% |
| 2007 FY | -140.04 Million CHF | -243.08% |
| 2006 FY | -40.82 Million CHF | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| BB Biotech AG | 304.39 Million CHF | 101.157% |
| Basilea Pharmaceutica AG | 116.11 Million CHF | 103.032% |
| Evolva Holding SA | -5.83 Million CHF | 39.693% |
| Idorsia Ltd | 1.05 Billion CHF | 100.333% |
| Kuros Biosciences AG | -8.69 Million CHF | 59.48% |
| Molecular Partners AG | -183.23 Million CHF | 98.078% |
| Relief Therapeutics Holding AG | -10.24 Million CHF | 65.631% |
| Santhera Pharmaceuticals Holding AG | -5.3 Million CHF | 33.663% |